A biocompatible anti-inflammatory material from loxoprofen with native and methyl-substituted β-cyclodextrin

초록

The increasing demand for readily soluble and biocompatible pharmaceuticals has led to the development of active pharmaceutical ingredients that utilize cyclodextrins (CDs) in the form of inclusion complexes. These products enhance the solubility and bioavailability of drugs. In this study, we developed inclusion complexes (ICs) of the anti-inflammatory drug loxoprofen (LXP) using native beta-cyclodextrin (BCD) and its methyl derivative (MCD). The formation of these complexes was confirmed through absorbance, fluorescence measurements, proton NMR, and ROESY analyses, indicating a 1:1 stoichiometric ratio between LXP and CDs. Proton NMR and cross-peaks of ROESY measurements revealed that LXP is partially encapsulated in both CDs. Computational data from DFT calculations further supported these findings, confirming the stability of the complexes. The inclusion of products significantly enhanced the solubility, bioavailability, and anti-inflammatory efficacy of LXP, suggesting improved therapeutic potential for inflammatory conditions. These results highlight the potential of CDs in strengthening the delivery and efficiency of LXP.

키워드